References
- WHO. Antimicrobial resistance. 2015 [cited Jun 23 2015]. Available from: http://www.who.int/mediacentre/factsheets/fs194/en/.
- Visser Kift E, Maartens G, Bamford C. Systemic review of the evidence for rational dosing of colistin. S Afr Med J. 2014;104(3):183–186.
- Landersdorfer CB, Nation RL. Colistin: how should it be dosed for the critically ill? Critic Care Med. 2015;36:126–135.
- Taketomo CK, Hodding JH, Kraus DM, editors. Pediatric & neonatal dosage handbook. 21st edition. United States: Lexi-Comp. 2014; p. 541–544.
- Yahav D, Farbman L, Leibovici L, et al. Colistin: new lessons on an old antibiotic. Clin Microbiol Inf. 2011;18:18–29.
- Micalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Annal Inten Care. 2011;1(30):1–6
- Ortwine JK, Kaye KS, Li J, et al. Colistin: understanding and applying recent pharmacokinetic advances. Pharmacotherapy. 2015;35(1):11–16.
- Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics and pharmacodynamics of “old” polymyxins: what is new? Diagn Microbiol Infect Dis. 2012;74:213–223.
- Couet W, Gregoire N, Marchand S, et al. Colistin pharmacokinetic: the fog is lifting. Clin Microbiol Infect. 2011;2011(18):30–39.
- Bergen PJ, Li J, Nation RL, et al. Comparison of once-twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother. 2008;61:636–642.
- Al Ramahi JW, Al Bashaireh A, Salman S. Colistin in critically ill patients: a critical review. Int Arab J Antimicrob Agents. 2014;4(2:2):1–15.
- Spapen H, Jacobs R, Van Gorp V, et al. Renal and neurological side effects of colistin in critically ill patients. Annal Intens Care. 2011;1:14-20.
- Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-Interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54(12):1720-6.
- Zusman O, Avni T, Leibovici L, et al. Systemic review and meta-analysis of in-vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013;57:5104–5111.
- Kumar P, Giri S, Shaikh F, et al. Safety and efficacy of intravenous colistin in children. Indian Pediatr. 2015;52(2):129–130.
- British National Formulary for children. the essential resource for clinical use of medicines in children. London: RCPCH Publication; 2014. p. P292.
- Tamma P, Newland J, Pannaraj P, et al. The use of intravenous colistin among children in the United States. Pediatr Infect Dis J. 2013;32(1):17–22.
- Van Saene HKF, Silvestri L, De la Cal AM. Infection control in the intensive care unit. Milan: Springer; 2005. p. 575–592.
- Jajoo M, Kumar V, Jain M, et al. Intravenous colistin administration in neonates. Pediatr Infect Dis J. 2011;30(3):218–221.
- Michalpulos A, Papadakis E. Inhaled anti-infective agents: emphasis on colistin. Infection. 2010;38:81–88.